These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2885419)

  • 41. Synthesis and evaluation of 1,5-benzodiazepines with bridged cycloalkyl substituents at the N-1 position as potent and selective CCK-B Ligands.
    Finizia G; Donati D; Pentassuglia G; Polinelli S; Tarzia G; Tranquillini ME; Ursini A
    Arch Pharm (Weinheim); 1998 Jan; 331(1):41-4. PubMed ID: 9507701
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
    Lin CW; Holladay MW; Barrett RW; Wolfram CA; Miller TR; Witte D; Kerwin JF; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): Optimization of the C3 amino substituent.
    Hirst GC; Aquino C; Birkemo L; Croom DK; Dezube M; Dougherty RW; Ervin GN; Grizzle MK; Henke B; James MK; Johnson MF; Momtahen T; Queen KL; Sherrill RG; Szewczyk J; Willson TM; Sugg EE
    J Med Chem; 1996 Dec; 39(26):5236-45. PubMed ID: 8978852
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer.
    Abbruzzese JL; Gholson CF; Daugherty K; Larson E; DuBrow R; Berlin R; Levin B
    Pancreas; 1992; 7(2):165-71. PubMed ID: 1553366
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 5-Phenyl-3-ureidobenzazepin-2-ones as cholecystokinin-B receptor antagonists.
    Lowe JA; Hageman DL; Drozda SE; McLean S; Bryce DK; Crawford RT; Zorn S; Morrone J; Bordner J
    J Med Chem; 1994 Oct; 37(22):3789-811. PubMed ID: 7966138
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of CCK receptors in a novel smooth muscle preparation from the guinea-pig stomach by use of the selective antagonists CI-988, L-365,260 and devazepide.
    Boyle SJ; Tang KW; Woodruff GN; McKnight AT
    Br J Pharmacol; 1993 Aug; 109(4):913-7. PubMed ID: 8401944
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutations within the cholecystokinin-B/gastrin receptor ligand 'pocket' interconvert the functions of nonpeptide agonists and antagonists.
    Bläker M; Ren Y; Gordon MC; Hsu JE; Beinborn M; Kopin AS
    Mol Pharmacol; 1998 Nov; 54(5):857-63. PubMed ID: 9804620
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Study of the states and populations of the rat pancreatic cholecystokinin receptor using the full peptide antagonist JMV 179.
    Silvente Poirot S; Hadjiivanova C; Escrieut C; Dufresne M; Martinez J; Vaysse N; Fourmy D
    Eur J Biochem; 1993 Mar; 212(2):529-38. PubMed ID: 8444190
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists.
    Makovec F; Bani M; Cereda R; Chisté R; Pacini MA; Revel L; Rovati LA; Rovati LC; Setnikar I
    Arzneimittelforschung; 1987 Nov; 37(11):1265-8. PubMed ID: 3440035
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A second generation of non-peptide cholecystokinin receptor antagonists and their possible therapeutic potential.
    Freedman SB; Patel S; Smith AJ; Chapman K; Fletcher A; Kemp JA; Marshall GR; Hargreaves RJ; Scholey K; Mellin EC
    Ann N Y Acad Sci; 1994 Mar; 713():312-8. PubMed ID: 8185173
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger".
    Aquino CJ; Armour DR; Berman JM; Birkemo LS; Carr RA; Croom DK; Dezube M; Dougherty RW; Ervin GN; Grizzle MK; Head JE; Hirst GC; James MK; Johnson MF; Miller LJ; Queen KL; Rimele TJ; Smith DN; Sugg EE
    J Med Chem; 1996 Jan; 39(2):562-9. PubMed ID: 8558528
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives.
    Corringer PJ; Weng JH; Ducos B; Durieux C; Boudeau P; Bohme A; Roques BP
    J Med Chem; 1993 Jan; 36(1):166-72. PubMed ID: 8421283
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and "mixed" CCK-A/CCK-B antagonists.
    Boden PR; Higginbottom M; Hill DR; Horwell DC; Hughes J; Rees DC; Roberts E; Singh L; Suman-Chauhan N; Woodruff GN
    J Med Chem; 1993 Mar; 36(5):552-65. PubMed ID: 7684452
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthesis and biological evaluation of new 3-aralkylamino-2-aryl-2H-1, 2,4-pyridothiadiazine 1,1-dioxides as potential CCK-receptor ligands.
    De Tullio P; Pirotte B; Neven P; Masereel B; Dewalque D; Diouf O; Podona T; Caignard D; Renard P; Delarge J
    J Pharm Pharmacol; 1997 May; 49(5):463-71. PubMed ID: 9178178
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of cholecystokinin peptides and GV 150013, a selective cholecystokininB receptor antagonist, on electrically evoked endogenous GABA release from rat cortical slices.
    Ferraro L; Beani L; Trist D; Reggiani A; Bianchi C
    J Neurochem; 1999 Nov; 73(5):1973-81. PubMed ID: 10537055
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Small synthetic ligands of the cholecystokinin-B/gastrin receptor can mimic the function of endogenous peptide hormones.
    Beinborn M; Chen C; DeMeo L; McBride EW; Kopin AS
    Yale J Biol Med; 1998; 71(3-4):337-46. PubMed ID: 10461364
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis and evaluation of N-(5-methyl-3-oxo-1,2- diphenyl-2,3-dihydro-1H-pyrazol-4-yl)-N'-phenylureas as cholecystokinin antagonists.
    Lattmann E; Sattayasai J; Boonprakob Y; Lattmann P; Singh H
    Arzneimittelforschung; 2005; 55(5):251-8. PubMed ID: 15960423
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quantitative structure-activity relationship studies on 5-phenyl-3-ureido-1,5-benzodiazepine as cholecystokinin-A receptor antagonists.
    Agrawal VK; Sharma R; Khadikar PV
    Bioorg Med Chem; 2002 Nov; 10(11):3571-81. PubMed ID: 12213472
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Postponement of satiety by blockade of brain cholecystokinin (CCK-B) receptors.
    Dourish CT; Rycroft W; Iversen SD
    Science; 1989 Sep; 245(4925):1509-11. PubMed ID: 2781294
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Asperlicin, a novel non-peptidal cholecystokinin antagonist from Aspergillus alliaceus. Fermentation, isolation and biological properties.
    Goetz MA; Lopez M; Monaghan RL; Chang RS; Lotti VJ; Chen TB
    J Antibiot (Tokyo); 1985 Dec; 38(12):1633-7. PubMed ID: 3005212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.